JP4118327B2
(ja)
|
1994-08-20 |
2008-07-16 |
ゲンダック・リミテッド |
Dna認識のための結合タンパク質におけるまたはそれに関連する改良
|
GB9824544D0
(en)
|
1998-11-09 |
1999-01-06 |
Medical Res Council |
Screening system
|
US7262055B2
(en)
|
1998-08-25 |
2007-08-28 |
Gendaq Limited |
Regulated gene expression in plants
|
US7285416B2
(en)
*
|
2000-01-24 |
2007-10-23 |
Gendaq Limited |
Regulated gene expression in plants
|
US6410248B1
(en)
|
1998-01-30 |
2002-06-25 |
Massachusetts Institute Of Technology |
General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
|
JP4309051B2
(ja)
|
1998-03-02 |
2009-08-05 |
マサチューセッツ インスティテュート オブ テクノロジー |
改善したリンカーを有するポリジンクフィンガータンパク質
|
US6977154B1
(en)
|
1998-03-17 |
2005-12-20 |
Gendaq Limited |
Nucleic acid binding proteins
|
US6140081A
(en)
|
1998-10-16 |
2000-10-31 |
The Scripps Research Institute |
Zinc finger binding domains for GNN
|
US7070934B2
(en)
|
1999-01-12 |
2006-07-04 |
Sangamo Biosciences, Inc. |
Ligand-controlled regulation of endogenous gene expression
|
US6599692B1
(en)
|
1999-09-14 |
2003-07-29 |
Sangamo Bioscience, Inc. |
Functional genomics using zinc finger proteins
|
US7013219B2
(en)
|
1999-01-12 |
2006-03-14 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
US6453242B1
(en)
|
1999-01-12 |
2002-09-17 |
Sangamo Biosciences, Inc. |
Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
|
US6534261B1
(en)
*
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
US20030104526A1
(en)
|
1999-03-24 |
2003-06-05 |
Qiang Liu |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
US6794136B1
(en)
|
2000-11-20 |
2004-09-21 |
Sangamo Biosciences, Inc. |
Iterative optimization in the design of binding proteins
|
US7030215B2
(en)
*
|
1999-03-24 |
2006-04-18 |
Sangamo Biosciences, Inc. |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
US7329728B1
(en)
|
1999-10-25 |
2008-02-12 |
The Scripps Research Institute |
Ligand activated transcriptional regulator proteins
|
ATE309536T1
(de)
|
1999-12-06 |
2005-11-15 |
Sangamo Biosciences Inc |
Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen
|
AU2693501A
(en)
*
|
2000-01-24 |
2001-07-31 |
Gendaq Ltd |
Nucleic acid binding polypeptides characterized by flexible linkers connected nucleic acid binding modules
|
WO2001059450A2
(en)
|
2000-02-08 |
2001-08-16 |
Sangamo Biosciences, Inc. |
Cells expressing zinc finger protein for drug discovery
|
US7923542B2
(en)
|
2000-04-28 |
2011-04-12 |
Sangamo Biosciences, Inc. |
Libraries of regulatory sequences, methods of making and using same
|
AU5391401A
(en)
|
2000-04-28 |
2001-11-12 |
Sangamo Biosciences Inc |
Targeted modification of chromatin structure
|
AU2001257421A1
(en)
|
2000-04-28 |
2001-11-12 |
Sangamo Biosciences, Inc. |
Pharmacogenomics and identification of drug targets by reconstruction of signal transduction pathways based on sequences of accessible regions
|
ATE374249T1
(de)
|
2000-04-28 |
2007-10-15 |
Sangamo Biosciences Inc |
Datenbanken von regulatorischen sequenzen, methoden zu ihrer herstellung und verwendung
|
US6511808B2
(en)
|
2000-04-28 |
2003-01-28 |
Sangamo Biosciences, Inc. |
Methods for designing exogenous regulatory molecules
|
US7011972B2
(en)
|
2000-07-18 |
2006-03-14 |
The Scripps Research Institute |
Fusion polypeptide comprising two ligand binding domains
|
JP2004504029A
(ja)
*
|
2000-07-18 |
2004-02-12 |
ノバルティス アクチエンゲゼルシャフト |
単鎖、一量体、リガンド依存性ポリペプチドスイッチを用いる遺伝子発現の調節
|
AU2001278496A1
(en)
*
|
2000-07-21 |
2002-02-05 |
Syngenta Participations Ag |
Zinc finger domain recognition code and uses thereof
|
AU2884102A
(en)
*
|
2000-12-07 |
2002-06-18 |
Sangamo Biosciences Inc |
Regulation of angiogenesis with zinc finger proteins
|
US7067317B2
(en)
*
|
2000-12-07 |
2006-06-27 |
Sangamo Biosciences, Inc. |
Regulation of angiogenesis with zinc finger proteins
|
AU2002225187A1
(en)
*
|
2001-01-22 |
2002-07-30 |
Sangamo Biosciences, Inc. |
Zinc finger polypeptides and their use
|
CA2435394C
(en)
|
2001-01-22 |
2018-01-09 |
Sangamo Biosciences, Inc. |
Modified zinc finger binding proteins
|
US7067617B2
(en)
*
|
2001-02-21 |
2006-06-27 |
The Scripps Research Institute |
Zinc finger binding domains for nucleotide sequence ANN
|
DE60233555D1
(de)
*
|
2001-02-21 |
2009-10-15 |
Novartis Ag |
Die nukleotidsequenz ann bindende zink-finger domänen
|
US20040197892A1
(en)
*
|
2001-04-04 |
2004-10-07 |
Michael Moore |
Composition binding polypeptides
|
ATE403676T1
(de)
|
2001-05-31 |
2008-08-15 |
Novartis Ag |
Neue östrogenrezeptorligandenbindungsdomänen varianten und neue liganden und pharmazeutische zusammensetzungen
|
US20040224385A1
(en)
*
|
2001-08-20 |
2004-11-11 |
Barbas Carlos F |
Zinc finger binding domains for cnn
|
US7262054B2
(en)
*
|
2002-01-22 |
2007-08-28 |
Sangamo Biosciences, Inc. |
Zinc finger proteins for DNA binding and gene regulation in plants
|
AU2003251286B2
(en)
*
|
2002-01-23 |
2007-08-16 |
The University Of Utah Research Foundation |
Targeted chromosomal mutagenesis using zinc finger nucleases
|
EP1481087A4
(de)
*
|
2002-02-07 |
2005-12-21 |
Scripps Research Inst |
Zinkfingerbibliotheken
|
US20030232410A1
(en)
*
|
2002-03-21 |
2003-12-18 |
Monika Liljedahl |
Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
|
WO2003104414A2
(en)
*
|
2002-06-11 |
2003-12-18 |
The Scripps Research Institute |
Artificial transcription factors
|
US7361635B2
(en)
|
2002-08-29 |
2008-04-22 |
Sangamo Biosciences, Inc. |
Simultaneous modulation of multiple genes
|
CA2497913C
(en)
*
|
2002-09-05 |
2014-06-03 |
California Institute Of Technology |
Use of chimeric nucleases to stimulate gene targeting
|
WO2004046387A1
(en)
*
|
2002-11-15 |
2004-06-03 |
Sangamo Biosciences, Inc. |
Methods and compositions for analysis of regulatory sequences
|
US8071285B1
(en)
|
2003-05-14 |
2011-12-06 |
Carl Henry Lawyer |
Zinc finger protein derivatives and methods of using same
|
US11311574B2
(en)
|
2003-08-08 |
2022-04-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US7888121B2
(en)
*
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US20120196370A1
(en)
|
2010-12-03 |
2012-08-02 |
Fyodor Urnov |
Methods and compositions for targeted genomic deletion
|
US8409861B2
(en)
*
|
2003-08-08 |
2013-04-02 |
Sangamo Biosciences, Inc. |
Targeted deletion of cellular DNA sequences
|
EP3222715A1
(de)
|
2003-08-08 |
2017-09-27 |
Sangamo BioSciences, Inc. |
Verfahren und zusammensetzungen für gezielte spaltung und rekombination
|
CA2539439C
(en)
*
|
2003-09-19 |
2012-10-23 |
Sangamo Biosciences, Inc. |
Engineered zinc finger proteins for regulation of gene expression
|
US7972854B2
(en)
|
2004-02-05 |
2011-07-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
EP1737498A2
(de)
*
|
2004-04-08 |
2007-01-03 |
Sangamo Biosciences Inc. |
Zink-finger-proteine zur behandlung von neuropathischen schmerzen
|
WO2005099771A2
(en)
*
|
2004-04-08 |
2005-10-27 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating neuropathic and neurodegenerative conditions
|
CA2561565C
(en)
*
|
2004-04-08 |
2013-11-26 |
Sangamo Biosciences, Inc. |
Methods for repression of phospholamban gene and modulating cardiac contractility
|
US20080131962A1
(en)
*
|
2006-05-25 |
2008-06-05 |
Sangamo Biosciences, Inc. |
Engineered cleavage half-domains
|
CA2579677A1
(en)
|
2004-09-16 |
2006-03-30 |
Sangamo Biosciences, Inc. |
Compositions and methods for protein production
|
EP1645633B1
(de)
|
2004-10-05 |
2011-09-21 |
SunGene GmbH |
Konstitutive Expressionskassette zur Regulierung der Expression in Pflanzen.
|
EP1655364A3
(de)
|
2004-11-05 |
2006-08-02 |
BASF Plant Science GmbH |
Expressionskassetten zur bevorzugten Expression in Pflanzensamen
|
EP1662000B1
(de)
|
2004-11-25 |
2011-03-30 |
SunGene GmbH |
Expressionskassetten zur bevorzugten Expression in pflanzlichen Schliesszellen
|
EP1666599A3
(de)
|
2004-12-04 |
2006-07-12 |
SunGene GmbH |
Expressionskassetten zur bevorzugten Expression in Mesophyll- und/oder Epidermiszellen in Pflanzen
|
EP1669455B1
(de)
|
2004-12-08 |
2009-10-28 |
SunGene GmbH |
Expressionskassetten für preferentiell vaskuläre Expression in Pflanzen
|
EP1669456A3
(de)
|
2004-12-11 |
2006-07-12 |
SunGene GmbH |
Expressionskasseten für meristembevorzugte Expression in Pflanzen
|
EP2184361A3
(de)
|
2005-02-09 |
2010-07-14 |
BASF Plant Science GmbH |
Expressionskassetten zur Regulation der Expression in einkeimblättrigen Pflanzen
|
CA2598307C
(en)
|
2005-02-26 |
2014-12-30 |
Basf Plant Science Gmbh |
Expression cassettes for seed-preferential expression in plants
|
US7358085B2
(en)
*
|
2005-02-28 |
2008-04-15 |
Sangamo Biosciences, Inc. |
Anti-angiogenic methods and compositions
|
US7790873B2
(en)
|
2005-05-10 |
2010-09-07 |
Basf Plant Science Gmbh |
Expression cassettes for seed-preferential expression in plants
|
WO2007014275A2
(en)
|
2005-07-26 |
2007-02-01 |
Sangamo Biosciences, Inc. |
Targeted integration and expression of exogenous nucleic acid sequences
|
JP2009504156A
(ja)
*
|
2005-08-11 |
2009-02-05 |
ザ スクリップス リサーチ インスティテュート |
Cnnに対するジンクフィンガー結合ドメイン
|
US20070122408A1
(en)
*
|
2005-10-20 |
2007-05-31 |
The Scripps Research Institute |
Fc Labeling for Immunostaining and Immunotargeting
|
US7833784B2
(en)
*
|
2005-11-28 |
2010-11-16 |
The Scripps Research Institute |
Zinc finger binding domains for TNN
|
US20070154989A1
(en)
*
|
2006-01-03 |
2007-07-05 |
The Scripps Research Institute |
Zinc finger domains specifically binding agc
|
US20070178499A1
(en)
*
|
2006-01-06 |
2007-08-02 |
The Scripps Research Institute |
Specific Labeling of Protein with Zinc Finger Tags and Use of Zinc-Finger-Tagged Proteins for Analysis
|
WO2007136685A2
(en)
*
|
2006-05-19 |
2007-11-29 |
Sangamo Biosciences, Inc. |
Methods and compositions for inactivation of dihydrofolate reductase
|
US7951925B2
(en)
|
2006-05-25 |
2011-05-31 |
Sangamo Biosciences, Inc. |
Methods and compositions for gene inactivation
|
CN105296527B
(zh)
|
2006-08-11 |
2020-11-27 |
陶氏益农公司 |
锌指核酸酶介导的同源重组
|
JP5188504B2
(ja)
*
|
2006-11-13 |
2013-04-24 |
サンガモ バイオサイエンシズ インコーポレイテッド |
ヒトグルココルチコイド受容体遺伝子座の修飾のための方法および組成物
|
JP5632610B2
(ja)
|
2006-12-14 |
2014-11-26 |
ダウ アグロサイエンシィズ エルエルシー |
最適化された非正準ジンクフィンガータンパク質
|
CA2675926A1
(en)
|
2007-02-16 |
2008-08-21 |
Basf Plant Science Gmbh |
Nucleic acid sequences for regulation of embryo-specific expression in monocotyledonous plants
|
WO2008133938A2
(en)
|
2007-04-26 |
2008-11-06 |
Sangamo Biosciences, Inc. |
Targeted integration into the ppp1r12c locus
|
US7919313B2
(en)
|
2007-07-12 |
2011-04-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT8) gene expression
|
US11235026B2
(en)
|
2007-09-27 |
2022-02-01 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modulating PD1
|
AU2008305568B2
(en)
|
2007-09-27 |
2013-11-21 |
Corteva Agriscience Llc |
Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes
|
WO2009042163A2
(en)
*
|
2007-09-27 |
2009-04-02 |
Sangamo Biosciences, Inc. |
Rapid in vivo identification of biologically active nucleases
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
AU2008317354B2
(en)
*
|
2007-10-25 |
2014-04-10 |
Ospedale San Raffaele S.R.L. |
Methods and compositions for targeted integration
|
CA2704271C
(en)
|
2007-12-03 |
2016-07-19 |
Syngenta Participations Ag |
Engineering enzymatically susceptible phytases
|
US20090215878A1
(en)
*
|
2008-02-08 |
2009-08-27 |
Sangamo Biosciences, Inc. |
Treatment of chronic pain with zinc finger proteins
|
DK2268129T3
(en)
|
2008-04-21 |
2015-09-28 |
Danziger Innovations Ltd |
PLANTEVIRUSEKSPRESSIONSVEKTORER AND USE THEREOF FOR GENERATING GENOTYPEVARIATIONER into plant genomes
|
CN102027118B
(zh)
|
2008-04-30 |
2014-07-30 |
桑比欧公司 |
含有dna甲基化状态改变的神经再生细胞
|
JP2011521643A
(ja)
|
2008-05-28 |
2011-07-28 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
Dna結合ドメインおよび切断ドメインを連結するための組成物
|
CA2893175C
(en)
*
|
2008-06-10 |
2016-09-06 |
Sangamo Biosciences, Inc. |
Methods and compositions for generation of bax- and bak-deficient cell lines
|
KR101759586B1
(ko)
|
2008-08-22 |
2017-07-19 |
상가모 테라퓨틱스, 인코포레이티드 |
표적화된 단일가닥 분할 및 표적화된 통합을 위한 방법 및 조성물
|
WO2010053518A2
(en)
*
|
2008-10-29 |
2010-05-14 |
Sangamo Biosciences, Inc. |
Methods and compositions for inactivating glutamine synthetase gene expression
|
WO2010056808A2
(en)
*
|
2008-11-12 |
2010-05-20 |
The Regents Of The University Of California |
Compositions and methods for re-programming and re-differentiating cells
|
US20110023146A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of genes involved in secretase-associated disorders
|
KR101803737B1
(ko)
|
2008-12-04 |
2017-12-01 |
상가모 테라퓨틱스, 인코포레이티드 |
징크 핑거 뉴클레아제를 이용한 랫트의 유전체 편집
|
US20110016543A1
(en)
*
|
2008-12-04 |
2011-01-20 |
Sigma-Aldrich Co. |
Genomic editing of genes involved in inflammation
|
US20110016540A1
(en)
*
|
2008-12-04 |
2011-01-20 |
Sigma-Aldrich Co. |
Genome editing of genes associated with trinucleotide repeat expansion disorders in animals
|
US20110023139A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of genes involved in cardiovascular disease
|
US20110023158A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Bovine genome editing with zinc finger nucleases
|
US20110023148A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genome editing of addiction-related genes in animals
|
US20110030072A1
(en)
*
|
2008-12-04 |
2011-02-03 |
Sigma-Aldrich Co. |
Genome editing of immunodeficiency genes in animals
|
US20110023151A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genome editing of abc transporters
|
US20110023140A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Rabbit genome editing with zinc finger nucleases
|
US20110016539A1
(en)
*
|
2008-12-04 |
2011-01-20 |
Sigma-Aldrich Co. |
Genome editing of neurotransmission-related genes in animals
|
US20110023149A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of genes involved in tumor suppression in animals
|
US20110023141A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of genes involved with parkinson's disease
|
US20110023147A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of prion disorder-related genes in animals
|
US20110023143A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of neurodevelopmental genes in animals
|
US20110023150A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genome editing of genes associated with schizophrenia in animals
|
US20110016541A1
(en)
*
|
2008-12-04 |
2011-01-20 |
Sigma-Aldrich Co. |
Genome editing of sensory-related genes in animals
|
US20110023144A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of genes involved in amyotrophyic lateral sclerosis disease
|
US20110023152A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genome editing of cognition related genes in animals
|
US20110023145A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of genes involved in autism spectrum disorders
|
US20110023153A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of genes involved in alzheimer's disease
|
US20110023154A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Silkworm genome editing with zinc finger nucleases
|
US20110016546A1
(en)
*
|
2008-12-04 |
2011-01-20 |
Sigma-Aldrich Co. |
Porcine genome editing with zinc finger nucleases
|
US20110023156A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Feline genome editing with zinc finger nucleases
|
BRPI0922641B1
(pt)
*
|
2008-12-17 |
2021-10-26 |
Dow Agrosciences Llc |
Método de integração de uma ou mais sequências de ácido nucleico exógenas no genoma de uma célula vegetal
|
US8551945B2
(en)
*
|
2009-02-04 |
2013-10-08 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating neuropathies
|
JP5932632B2
(ja)
|
2009-03-20 |
2016-06-15 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
改変された亜鉛フィンガータンパク質を使用したcxcr4の修飾
|
WO2010117464A1
(en)
*
|
2009-04-09 |
2010-10-14 |
Sangamo Biosciences, Inc. |
Targeted integration into stem cells
|
US8772008B2
(en)
*
|
2009-05-18 |
2014-07-08 |
Sangamo Biosciences, Inc. |
Methods and compositions for increasing nuclease activity
|
AU2010266705B2
(en)
|
2009-06-30 |
2014-06-05 |
Sangamo Therapeutics, Inc. |
Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
|
US9234016B2
(en)
*
|
2009-07-28 |
2016-01-12 |
Sangamo Biosciences, Inc. |
Engineered zinc finger proteins for treating trinucleotide repeat disorders
|
DK2462230T3
(en)
*
|
2009-08-03 |
2015-10-19 |
Recombinetics Inc |
METHODS AND COMPOSITIONS FOR TARGETED RE-MODIFICATION
|
AU2010282958B2
(en)
|
2009-08-11 |
2015-05-21 |
Sangamo Therapeutics, Inc. |
Organisms homozygous for targeted modification
|
WO2011048600A1
(en)
|
2009-10-21 |
2011-04-28 |
Danziger Innovations Ltd. |
Generating genotypic variations in plant genomes by gamete infection
|
RU2568056C2
(ru)
|
2009-10-22 |
2015-11-10 |
ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи |
Конструируемые белки с цинковыми пальцами, направленные на гены растений, вовлеченные в биосинтез жирных кислот
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
WO2011064736A1
(en)
|
2009-11-27 |
2011-06-03 |
Basf Plant Science Company Gmbh |
Optimized endonucleases and uses thereof
|
US10260062B2
(en)
|
2010-01-22 |
2019-04-16 |
Sangamo Therapeutics, Inc. |
Targeted genomic alteration
|
JP6137596B2
(ja)
|
2010-02-08 |
2017-05-31 |
サンガモ セラピューティクス, インコーポレイテッド |
遺伝子操作された切断ハーフドメイン
|
EP2660318A1
(de)
|
2010-02-09 |
2013-11-06 |
Sangamo BioSciences, Inc. |
Gezielte Genommodifikation mit partiell einzelsträngigen Donatormolekülen
|
CN102939377B
(zh)
|
2010-04-26 |
2016-06-08 |
桑格摩生物科学股份有限公司 |
使用锌指核酸酶对Rosa位点进行基因组编辑
|
WO2011139349A1
(en)
|
2010-05-03 |
2011-11-10 |
Sangamo Biosciences, Inc. |
Compositions for linking zinc finger modules
|
CA2993567C
(en)
|
2010-07-21 |
2022-06-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of a t-cell receptor gene
|
CA2811364C
(en)
|
2010-09-27 |
2022-01-04 |
Sangamo Biosciences, Inc. |
Methods and compositions for inhibiting viral entry into cells
|
AU2011316575B2
(en)
|
2010-10-12 |
2015-10-29 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treating hemophilia B
|
WO2012094132A1
(en)
|
2011-01-05 |
2012-07-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for gene correction
|
WO2012127373A1
(en)
|
2011-03-18 |
2012-09-27 |
Basf Plant Science Company Gmbh |
Promoters for regulating expression in plants
|
US20140186340A1
(en)
|
2011-04-08 |
2014-07-03 |
Gilead Biologics, Inc. |
Methods and Compositions for Normalization of Tumor Vasculature by Inhibition of LOXL2
|
US9161995B2
(en)
|
2011-07-25 |
2015-10-20 |
Sangamo Biosciences, Inc. |
Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
|
EP3498833B1
(de)
|
2011-09-21 |
2023-08-16 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zur regulierung der transgenexpression
|
US8951752B2
(en)
|
2011-10-20 |
2015-02-10 |
University Of Iowa Research Foundation |
N-demethyase genes and uses thereof
|
EP2771457B1
(de)
|
2011-10-27 |
2017-11-22 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zur veränderung des hprt-locus
|
WO2013112917A1
(en)
|
2012-01-27 |
2013-08-01 |
Sanbio, Inc. |
Methods and compositions for modulating angiogenesis and vasculogenesis
|
CN108285491B
(zh)
|
2012-02-29 |
2021-08-10 |
桑格摩生物科学股份有限公司 |
治疗亨廷顿氏病的方法和组合物
|
WO2013158309A2
(en)
|
2012-04-18 |
2013-10-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Non-disruptive gene targeting
|
WO2013163628A2
(en)
|
2012-04-27 |
2013-10-31 |
Duke University |
Genetic correction of mutated genes
|
CN104428414B
(zh)
|
2012-05-02 |
2022-01-21 |
陶氏益农公司 |
苹果酸脱氢酶的靶向修饰
|
CN104471067B
(zh)
|
2012-05-07 |
2020-08-14 |
桑格摩生物治疗股份有限公司 |
用于核酸酶介导的转基因靶向整合的方法和组合物
|
WO2013169398A2
(en)
|
2012-05-09 |
2013-11-14 |
Georgia Tech Research Corporation |
Systems and methods for improving nuclease specificity and activity
|
WO2013187957A1
(en)
|
2012-06-15 |
2013-12-19 |
University Of Iowa Research Foundation |
Caffeine responsive promoters and regulatory genes
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
EP2872154B1
(de)
|
2012-07-11 |
2017-05-31 |
Sangamo BioSciences, Inc. |
Verfahren und zusammensetzungen zur freisetzung von biologischen wirkstoffen
|
HUE030799T2
(en)
|
2012-07-11 |
2017-06-28 |
Sangamo Biosciences Inc |
Methods and preparations for the treatment of lysosomal storage diseases
|
AU2013308770B2
(en)
|
2012-08-29 |
2019-01-17 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treatment of a genetic condition
|
EP3750999B1
(de)
|
2012-09-04 |
2022-06-29 |
The Scripps Research Institute |
Chimäre polypeptide mit gerichteter bindungsspezifität
|
CA2884162C
(en)
|
2012-09-07 |
2020-12-29 |
Dow Agrosciences Llc |
Fad3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
|
UA118090C2
(uk)
|
2012-09-07 |
2018-11-26 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
|
UA119135C2
(uk)
|
2012-09-07 |
2019-05-10 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб отримання трансгенної рослини
|
EP2906684B8
(de)
|
2012-10-10 |
2020-09-02 |
Sangamo Therapeutics, Inc. |
T-zell-modifizierende verbindungen und verwendungen davon
|
AU2013355327A1
(en)
|
2012-12-05 |
2015-06-11 |
Sangamo Therapeutics, Inc. |
Methods and compositions for regulation of metabolic disorders
|
WO2014093768A1
(en)
|
2012-12-13 |
2014-06-19 |
Ainley W Michael |
Precision gene targeting to a particular locus in maize
|
WO2014130955A1
(en)
|
2013-02-25 |
2014-08-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for enhancing nuclease-mediated gene disruption
|
EP2975942B1
(de)
|
2013-03-21 |
2018-08-08 |
Sangamo Therapeutics, Inc. |
Gezielte disruption von t-zell rezeptorgenen mit manipulierten zinkfinger-proteinnukleasen
|
JP2016514480A
(ja)
|
2013-04-05 |
2016-05-23 |
ダウ アグロサイエンシィズ エルエルシー |
植物のゲノム内に外因性配列を組み込むための方法および組成物
|
CA2910427C
(en)
|
2013-05-10 |
2024-02-20 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
WO2014186435A2
(en)
|
2013-05-14 |
2014-11-20 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for reducing neointima formation
|
CN116083487A
(zh)
|
2013-05-15 |
2023-05-09 |
桑格摩生物治疗股份有限公司 |
用于治疗遗传病状的方法和组合物
|
CA2920899C
(en)
|
2013-08-28 |
2023-02-28 |
Sangamo Biosciences, Inc. |
Compositions for linking dna-binding domains and cleavage domains
|
CA2926078C
(en)
|
2013-10-17 |
2021-11-16 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
|
CN105899665B
(zh)
|
2013-10-17 |
2019-10-22 |
桑格摩生物科学股份有限公司 |
用于核酸酶介导的基因组工程改造的递送方法和组合物
|
AU2014341927B2
(en)
|
2013-11-04 |
2017-12-14 |
Corteva Agriscience Llc |
Optimal maize loci
|
CA2928666C
(en)
|
2013-11-04 |
2023-05-23 |
Dow Agrosciences Llc |
Optimal maize loci for targeted genome modification
|
EP3066109A4
(de)
|
2013-11-04 |
2017-11-29 |
Dow AgroSciences LLC |
Optimale sojabohnen-loci
|
MX358066B
(es)
|
2013-11-04 |
2018-08-03 |
Dow Agrosciences Llc |
Óptimos loci de soya.
|
CA2929179A1
(en)
|
2013-11-11 |
2015-05-14 |
Sangamo Biosciences, Inc. |
Htt genetic repressor, viral vector, and uses thereof
|
DK3068881T3
(en)
|
2013-11-13 |
2019-04-15 |
Childrens Medical Center |
NUCLEASE-MEDIATED REGULATION OF GENEPRESSION
|
US9932607B2
(en)
|
2013-11-15 |
2018-04-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Site-specific integration of transgenes into human cells
|
US9771403B2
(en)
|
2013-12-09 |
2017-09-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treating hemophilia
|
US10774338B2
(en)
|
2014-01-16 |
2020-09-15 |
The Regents Of The University Of California |
Generation of heritable chimeric plant traits
|
US10072066B2
(en)
|
2014-02-03 |
2018-09-11 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treatment of a beta thalessemia
|
US10370680B2
(en)
|
2014-02-24 |
2019-08-06 |
Sangamo Therapeutics, Inc. |
Method of treating factor IX deficiency using nuclease-mediated targeted integration
|
TW201538518A
(zh)
|
2014-02-28 |
2015-10-16 |
Dow Agrosciences Llc |
藉由嵌合基因調控元件所賦予之根部特異性表現
|
US9624498B2
(en)
|
2014-03-18 |
2017-04-18 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of zinc finger protein expression
|
WO2015143177A1
(en)
|
2014-03-21 |
2015-09-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Genome editing without nucleases
|
US10507232B2
(en)
|
2014-04-02 |
2019-12-17 |
University Of Florida Research Foundation, Incorporated |
Materials and methods for the treatment of latent viral infection
|
US9522936B2
(en)
|
2014-04-24 |
2016-12-20 |
Sangamo Biosciences, Inc. |
Engineered transcription activator like effector (TALE) proteins
|
US11110154B2
(en)
|
2014-05-08 |
2021-09-07 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treating Huntington's Disease
|
US11918695B2
(en)
|
2014-05-09 |
2024-03-05 |
Yale University |
Topical formulation of hyperbranched polymer-coated particles
|
EP3139909A4
(de)
|
2014-05-09 |
2018-01-03 |
Yale University |
Topische formulierung von hyperverzweigten polyglycerolbeschichteten partikeln
|
WO2015175642A2
(en)
|
2014-05-13 |
2015-11-19 |
Sangamo Biosciences, Inc. |
Methods and compositions for prevention or treatment of a disease
|
WO2015188065A1
(en)
|
2014-06-05 |
2015-12-10 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease design
|
CA2954201A1
(en)
|
2014-07-08 |
2016-01-14 |
Vib Vzw |
Means and methods to increase plant yield
|
NZ728159A
(en)
|
2014-07-14 |
2018-08-31 |
Univ Washington State |
Nanos2 knock-out that ablates germline cells
|
MA40253A
(fr)
|
2014-07-15 |
2017-05-24 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
WO2016011381A1
(en)
|
2014-07-18 |
2016-01-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Reducing cxcr4 expression and/or function to enhance engraftment of hematopoietic stem cells
|
WO2016014837A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Gene editing for hiv gene therapy
|
US9816074B2
(en)
|
2014-07-25 |
2017-11-14 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
|
WO2016019144A2
(en)
|
2014-07-30 |
2016-02-04 |
Sangamo Biosciences, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
EP3878948A1
(de)
|
2014-09-16 |
2021-09-15 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen für nukleasevermitteltes genom-engineering und korrektur bei hämotopoietischen stammzellen
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
WO2016118726A2
(en)
|
2015-01-21 |
2016-07-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for identification of highly specific nucleases
|
CN114058582A
(zh)
|
2015-01-26 |
2022-02-18 |
菲特治疗公司 |
用于诱导造血细胞分化的方法和组合物
|
US10676726B2
(en)
|
2015-02-09 |
2020-06-09 |
Duke University |
Compositions and methods for epigenome editing
|
JP6964843B2
(ja)
*
|
2015-03-31 |
2021-11-10 |
国立研究開発法人農業・食品産業技術総合研究機構 |
バイナリー遺伝子発現システム
|
ES2959608T3
(es)
|
2015-04-03 |
2024-02-27 |
Dana Farber Cancer Inst Inc |
Composición y métodos de edición del genoma de células B
|
BR112017021703B1
(pt)
|
2015-04-15 |
2023-11-28 |
Corteva Agriscience Llc |
Promotor de planta para expressão de transgene
|
EP3283633A2
(de)
|
2015-04-15 |
2018-02-21 |
Dow AgroSciences LLC |
Pflanzenpromoter zur transgenen expression
|
US11845928B2
(en)
|
2015-05-04 |
2023-12-19 |
Tsinghua University |
Methods and kits for fragmenting DNA
|
US10179918B2
(en)
|
2015-05-07 |
2019-01-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for increasing transgene activity
|
IL284707B2
(en)
|
2015-05-12 |
2024-01-01 |
Sangamo Therapeutics Inc |
Regulation of nuclease-mediated gene expression
|
US20180161368A1
(en)
|
2015-05-29 |
2018-06-14 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
EP3322297A4
(de)
|
2015-07-13 |
2019-04-17 |
Sangamo Therapeutics, Inc. |
Freisetzungsverfahren und zusammensetzungen für nukleasevermitteltes genomengineering
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
CN109475107A
(zh)
|
2015-08-06 |
2019-03-15 |
密苏里大学管理者 |
具有修饰的cd163基因的抗病原体动物
|
TW201718861A
(zh)
|
2015-09-22 |
2017-06-01 |
道禮責任有限公司 |
用於轉殖基因表現之植物啟動子及3’utr
|
TW201718862A
(zh)
|
2015-09-22 |
2017-06-01 |
Dow Agrosciences Llc |
用於轉殖基因表現之植物啟動子及3’utr
|
CN108348576B
(zh)
|
2015-09-23 |
2022-01-11 |
桑格摩生物治疗股份有限公司 |
Htt阻抑物及其用途
|
US11970710B2
(en)
|
2015-10-13 |
2024-04-30 |
Duke University |
Genome engineering with Type I CRISPR systems in eukaryotic cells
|
WO2017070298A1
(en)
|
2015-10-22 |
2017-04-27 |
Dow Agrosciences Llc |
Plant promoter for transgene expression
|
SG11201803144WA
(en)
|
2015-11-04 |
2018-05-30 |
Fate Therapeutics Inc |
Genomic engineering of pluripotent cells
|
CA3003152A1
(en)
|
2015-11-04 |
2017-05-11 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
US20170121726A1
(en)
|
2015-11-04 |
2017-05-04 |
Dow Agrosciences Llc |
Plant promoter for transgene expression
|
EP3380622A4
(de)
|
2015-11-23 |
2019-08-07 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zum immunitäts-engineering
|
CA3008413A1
(en)
|
2015-12-18 |
2017-06-22 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the t cell receptor
|
EA201891212A1
(ru)
|
2015-12-18 |
2019-01-31 |
Сангамо Терапьютикс, Инк. |
Адресная дезорганизация клеточного рецептора гкгс
|
SG11201805680SA
(en)
|
2016-01-15 |
2018-07-30 |
Sangamo Therapeutics Inc |
Methods and compositions for the treatment of neurologic disease
|
EP3411056A4
(de)
|
2016-02-02 |
2019-10-02 |
Sangamo Therapeutics, Inc. |
Zusammensetzungen zur vernetzung von dna-bindungsdomänen und -spaltungsdomänen
|
AU2017221424A1
(en)
|
2016-02-16 |
2018-09-20 |
Yale University |
Compositions and methods for treatment of cystic fibrosis
|
US11136597B2
(en)
|
2016-02-16 |
2021-10-05 |
Yale University |
Compositions for enhancing targeted gene editing and methods of use thereof
|
AU2017238512B2
(en)
|
2016-03-23 |
2022-12-08 |
Dana-Farber Cancer Institute, Inc. |
Methods for enhancing the efficiency of gene editing
|
US20190117799A1
(en)
|
2016-04-01 |
2019-04-25 |
The Brigham And Women's Hospital, Inc. |
Stimuli-responsive nanoparticles for biomedical applications
|
EP3448997B1
(de)
|
2016-04-27 |
2020-10-14 |
Massachusetts Institute of Technology |
Stabile nanoskalige nukleinsäureanordnungen und verfahren dafür
|
US11514331B2
(en)
|
2016-04-27 |
2022-11-29 |
Massachusetts Institute Of Technology |
Sequence-controlled polymer random access memory storage
|
MA45491A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
|
MA45455A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Procédé d'identification d'épitopes peptidiques, molécules qui se lient à de tels épitopes et utilisations associées
|
AU2017295720B2
(en)
|
2016-07-13 |
2021-07-22 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
WO2018022904A2
(en)
|
2016-07-27 |
2018-02-01 |
Case Western Reserve University |
Compounds and methods of promoting myelination
|
JP7066126B2
(ja)
|
2016-08-09 |
2022-05-13 |
ブイアイビー ブイゼットダブリュ |
セルロースシンターゼ阻害剤および突然変異体植物
|
PL3504229T3
(pl)
|
2016-08-24 |
2022-04-19 |
Sangamo Therapeutics, Inc. |
Regulacja ekspresji genów przy użyciu nukleaz poddanych inżynierii
|
EP3504327B1
(de)
|
2016-08-24 |
2021-10-06 |
Sangamo Therapeutics, Inc. |
Manipulierte zielspezifische nukleasen
|
AU2017324462B2
(en)
|
2016-09-07 |
2024-03-21 |
Sangamo Therapeutics, Inc. |
Modulation of liver genes
|
CA3038520A1
(en)
|
2016-10-03 |
2018-04-12 |
Dow Agrosciences Llc |
Plant promoter for transgene expression
|
MX2019003768A
(es)
|
2016-10-03 |
2019-06-24 |
Juno Therapeutics Inc |
Moleculas de enlace especificas de hpv.
|
US10400246B2
(en)
|
2016-10-03 |
2019-09-03 |
Dow Agrosciences Llc |
Plant promoter for transgene expression
|
EP3523422A1
(de)
|
2016-10-05 |
2019-08-14 |
FUJIFILM Cellular Dynamics, Inc. |
Erzeugung reifer linien aus induzierten pluripotenten stammzellen mit mecp2-unterbrechung
|
MA46649A
(fr)
|
2016-10-13 |
2019-08-21 |
Juno Therapeutics Inc |
Méthodes et compositions d'immunothérapie impliquant des modulateurs de la voie métabolique du tryptophane
|
BR112019007210A2
(pt)
|
2016-10-20 |
2019-08-13 |
Sangamo Therapeutics Inc |
métodos e composições para o tratamento da doença de fabry
|
US11766400B2
(en)
|
2016-10-24 |
2023-09-26 |
Yale University |
Biodegradable contraceptive implants
|
WO2018081775A1
(en)
|
2016-10-31 |
2018-05-03 |
Sangamo Therapeutics, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
EP3548616A4
(de)
|
2016-12-01 |
2020-05-13 |
Sangamo Therapeutics, Inc. |
Tau-modulatoren und verfahren und zusammensetzungen zur abgabe davon
|
CA3045323A1
(en)
|
2016-12-02 |
2018-06-07 |
Juno Therapeutics, Inc. |
Engineered b cells and related compositions and methods
|
CN110249046A
(zh)
|
2016-12-05 |
2019-09-17 |
朱诺治疗学股份有限公司 |
用于过继细胞疗法的工程化细胞的产生
|
MA49610A
(fr)
|
2016-12-08 |
2020-05-27 |
Univ Case Western Reserve |
Procédés et compositions pour améliorer la production de myéline fonctionnelle
|
WO2018112470A1
(en)
|
2016-12-16 |
2018-06-21 |
The Brigham And Women's Hospital, Inc. |
Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
|
EP3585895A1
(de)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Zusammensetzungen und verfahren zur geneditierung
|
WO2018187493A1
(en)
|
2017-04-04 |
2018-10-11 |
Yale University |
Compositions and methods for in utero delivery
|
KR20190140950A
(ko)
|
2017-04-20 |
2019-12-20 |
오레곤 헬스 앤드 사이언스 유니버시티 |
인간 유전자 교정
|
IL301115A
(en)
|
2017-04-28 |
2023-05-01 |
Acuitas Therapeutics Inc |
New lipid carbonyl and lipid nanoparticle formulations for delivery of nucleic acids
|
CA3059793A1
(en)
|
2017-05-03 |
2018-11-08 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene
|
US20200370058A1
(en)
|
2017-06-06 |
2020-11-26 |
Zymergen Inc. |
A htp genomic engineering platform for improving escherichia coli
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
MX2020003536A
(es)
|
2017-10-03 |
2020-09-14 |
Juno Therapeutics Inc |
Moleculas de union especifica a virus de papiloma humano (hpv).
|
US11851679B2
(en)
|
2017-11-01 |
2023-12-26 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
CA3079748A1
(en)
|
2017-11-09 |
2019-05-16 |
Sangamo Therapeutics, Inc. |
Genetic modification of cytokine inducible sh2-containing protein (cish) gene
|
US10940171B2
(en)
|
2017-11-10 |
2021-03-09 |
Massachusetts Institute Of Technology |
Microbial production of pure single stranded nucleic acids
|
US10953036B2
(en)
|
2017-11-20 |
2021-03-23 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods of modulating HIF-2A to improve muscle generation and repair
|
SG11202005173SA
(en)
|
2017-12-22 |
2020-06-29 |
Fate Therapeutics Inc |
Enhanced immune effector cells and use thereof
|
EA202091708A1
(ru)
|
2018-01-17 |
2020-11-10 |
Вертекс Фармасьютикалз Инкорпорейтед |
Ингибиторы днк-пк
|
CA3089587A1
(en)
|
2018-02-08 |
2019-08-15 |
Sangamo Therapeutics, Inc. |
Engineered target specific nucleases
|
KR20200127250A
(ko)
|
2018-03-29 |
2020-11-10 |
페이트 세러퓨틱스, 인코포레이티드 |
조작된 면역 효과기 세포 및 이의 용도
|
MA52193A
(fr)
|
2018-04-05 |
2021-02-17 |
Juno Therapeutics Inc |
Récepteurs de lymphocytes t et cellules modifiées les exprimant
|
MX2020010461A
(es)
|
2018-04-05 |
2021-01-15 |
Juno Therapeutics Inc |
Linfocitos t que expresan un receptor recombinante, polinucleotidos y metodos relacionados.
|
BR112020020245A2
(pt)
|
2018-04-05 |
2021-04-06 |
Editas Medicine, Inc. |
Métodos de produzir células expressando um receptor recombinante e composições relacionadas
|
WO2019204457A1
(en)
|
2018-04-18 |
2019-10-24 |
Sangamo Therapeutics, Inc. |
Zinc finger protein compositions for modulation of huntingtin (htt)
|
CA3099364A1
(en)
|
2018-05-11 |
2019-11-14 |
Crispr Therapeutics Ag |
Methods and compositions for treating cancer comprising engineered t cells comprising modified chimeric antigen receptors
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
GB201809273D0
(en)
|
2018-06-06 |
2018-07-25 |
Vib Vzw |
Novel mutant plant cinnamoyl-coa reductase proteins
|
EP3800998A1
(de)
|
2018-06-07 |
2021-04-14 |
The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) |
Verfahren zur regenerierung und transformation von cannabis
|
EP3802839A1
(de)
|
2018-06-07 |
2021-04-14 |
The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) |
Nukleinsäurekonstrukte und verfahren zu deren verwendung
|
EP3830278A4
(de)
|
2018-08-01 |
2022-05-25 |
University of Georgia Research Foundation, Inc. |
Zusammensetzungen und verfahren zur verbesserung der embryoentwicklung
|
IL280951B1
(en)
|
2018-08-23 |
2024-04-01 |
Sangamo Therapeutics Inc |
Engineered target-specific base editors
|
US20210338815A1
(en)
|
2018-08-31 |
2021-11-04 |
Yale University |
Compositions and methods for enhancing triplex and nuclease-based gene editing
|
CA3111711A1
(en)
|
2018-09-18 |
2020-03-26 |
Sangamo Therapeutics, Inc. |
Programmed cell death 1 (pd1) specific nucleases
|
EP3877419A1
(de)
|
2018-11-07 |
2021-09-15 |
CRISPR Therapeutics AG |
Anti-liv1-immunzellen-krebstherapie
|
BR112021008083A2
(pt)
|
2018-11-07 |
2021-08-10 |
Crispr Therapeutics Ag |
terapia contra o câncer com célula imunológica anti-ptk7
|
WO2020095107A1
(en)
|
2018-11-07 |
2020-05-14 |
Crispr Therapeutics Ag |
Anti-cd33 immune cell cancer therapy
|
WO2020112195A1
(en)
|
2018-11-30 |
2020-06-04 |
Yale University |
Compositions, technologies and methods of using plerixafor to enhance gene editing
|
AU2019391114A1
(en)
|
2018-12-05 |
2021-06-24 |
Vertex Pharmaceuticals Incorporated |
Gene-editing systems for editing a cystic fibrosis transmembrane regulator (CFTR) gene
|
GB201820109D0
(en)
|
2018-12-11 |
2019-01-23 |
Vib Vzw |
Plants with a lignin trait and udp-glycosyltransferase mutation
|
CN113474328A
(zh)
|
2019-01-11 |
2021-10-01 |
爱康泰生治疗公司 |
用于脂质纳米颗粒递送活性剂的脂质
|
US11419932B2
(en)
|
2019-01-24 |
2022-08-23 |
Massachusetts Institute Of Technology |
Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom
|
AU2019428629A1
(en)
|
2019-02-06 |
2021-01-28 |
Sangamo Therapeutics, Inc. |
Method for the treatment of mucopolysaccharidosis type I
|
CN114174327A
(zh)
|
2019-03-08 |
2022-03-11 |
黑曜石疗法公司 |
用于可调整调控的cd40l组合物和方法
|
MX2021012152A
(es)
|
2019-04-02 |
2021-11-03 |
Sangamo Therapeutics Inc |
Metodos para el tratamiento de beta-talasemia.
|
WO2020219726A1
(en)
|
2019-04-23 |
2020-10-29 |
Sangamo Therapeutics, Inc. |
Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof
|
AU2020265741A1
(en)
|
2019-05-01 |
2021-11-25 |
Editas Medicine, Inc. |
Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
|
WO2020223571A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
US11905532B2
(en)
|
2019-06-25 |
2024-02-20 |
Massachusetts Institute Of Technology |
Compositions and methods for molecular memory storage and retrieval
|
CA3144871A1
(en)
|
2019-06-27 |
2020-12-30 |
Crispr Therapeutics Ag |
Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
|
JP2022543112A
(ja)
|
2019-08-01 |
2022-10-07 |
サナ バイオテクノロジー,インコーポレイテッド |
Dux4発現細胞およびそれらの使用
|
JP2022546317A
(ja)
|
2019-08-23 |
2022-11-04 |
サナ バイオテクノロジー,インコーポレイテッド |
Cd24発現細胞およびそれらの用途
|
US20230227583A1
(en)
|
2019-08-30 |
2023-07-20 |
Yale University |
Compositions and methods for delivery of nucleic acids to cells
|
BR112022003891A2
(pt)
|
2019-09-06 |
2022-05-31 |
Crispr Therapeutics Ag |
Células t geneticamente manipuladas possuindo persistência melhorada em cultura
|
WO2021067864A1
(en)
|
2019-10-02 |
2021-04-08 |
Sangamo Therapeutics, Inc. |
Zinc finger protein transcription factors for treatment of prion disease
|
AU2020376048A1
(en)
|
2019-11-01 |
2022-06-02 |
Sangamo Therapeutics, Inc. |
Compositions and methods for genome engineering
|
US20210130828A1
(en)
|
2019-11-01 |
2021-05-06 |
Sangamo Therapeutics, Inc. |
Gin recombinase variants
|
CN115210250A
(zh)
|
2020-01-08 |
2022-10-18 |
黑曜石疗法公司 |
用于可调节性调控转录的组合物和方法
|
WO2021155065A1
(en)
|
2020-01-28 |
2021-08-05 |
The Broad Institute, Inc. |
Base editors, compositions, and methods for modifying the mitochondrial genome
|
EP4125961A1
(de)
|
2020-03-25 |
2023-02-08 |
Sana Biotechnology, Inc. |
Hypoimmunogene nervenzellen zur behandlung von neurologischen erkrankungen und zuständen
|
CA3177621A1
(en)
|
2020-05-06 |
2021-11-11 |
Alexandre Juillerat |
Methods to genetically modify cells for delivery of therapeutic proteins
|
EP4146812A1
(de)
|
2020-05-06 |
2023-03-15 |
Cellectis S.A. |
Verfahren zur gezielten einführung exogener sequenzen in zelluläre genome
|
WO2021231661A2
(en)
|
2020-05-13 |
2021-11-18 |
Juno Therapeutics, Inc. |
Process for producing donor-batched cells expressing a recombinant receptor
|
WO2021236852A1
(en)
|
2020-05-20 |
2021-11-25 |
Sana Biotechnology, Inc. |
Methods and compositions for treatment of viral infections
|
WO2021247836A1
(en)
|
2020-06-03 |
2021-12-09 |
Board Of Regents, The University Of Texas System |
Methods for targeting shp-2 to overcome resistance
|
KR20230042283A
(ko)
|
2020-06-26 |
2023-03-28 |
주노 테라퓨틱스 게엠베하 |
재조합 수용체를 조건부로 발현하는 조작된 t 세포, 관련된 폴리뉴클레오티드 및 방법
|
WO2022016070A1
(en)
|
2020-07-16 |
2022-01-20 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|
AU2021325941A1
(en)
|
2020-08-13 |
2023-03-09 |
Sana Biotechnology, Inc. |
Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
|
EP4204545A2
(de)
|
2020-08-25 |
2023-07-05 |
Kite Pharma, Inc. |
T-zellen mit verbesserter funktionalität
|
AU2021331785A1
(en)
|
2020-08-31 |
2023-03-30 |
Gennao Bio, Inc. |
Compositions and methods for delivery of nucleic acids to cells
|
WO2022064428A1
(en)
|
2020-09-23 |
2022-03-31 |
Crispr Therapeutics Ag |
Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence
|
JP2023542705A
(ja)
|
2020-09-25 |
2023-10-11 |
サンガモ セラピューティクス, インコーポレイテッド |
核酸塩基編集のためのジンクフィンガー融合タンパク質
|
WO2022098787A1
(en)
|
2020-11-04 |
2022-05-12 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
WO2022101641A1
(en)
|
2020-11-16 |
2022-05-19 |
Pig Improvement Company Uk Limited |
Influenza a-resistant animals having edited anp32 genes
|
KR20230118887A
(ko)
|
2020-12-03 |
2023-08-14 |
센츄리 쎄라퓨틱스 인코포레이티드 |
유전자 조작 세포 및 이의 용도
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
WO2022137181A1
(en)
|
2020-12-23 |
2022-06-30 |
Crispr Therapeutics Ag |
Co-use of lenalidomide with car-t cells
|
JP2024501971A
(ja)
|
2020-12-31 |
2024-01-17 |
サナ バイオテクノロジー,インコーポレイテッド |
Car-t活性を調節するための方法及び組成物
|
WO2022155265A2
(en)
|
2021-01-12 |
2022-07-21 |
Mitolab Inc. |
Context-dependent, double-stranded dna-specific deaminases and uses thereof
|
EP4305153A1
(de)
|
2021-03-09 |
2024-01-17 |
CRISPR Therapeutics AG |
Genetisch veränderte t-zellen mit ptpn2-knockout mit verbesserter funktionalität und antitumoraktivität
|
JP2024511420A
(ja)
|
2021-03-22 |
2024-03-13 |
ジュノー セラピューティクス インコーポレイテッド |
ウイルスベクター粒子の効力を評価する方法
|
EP4319799A1
(de)
|
2021-04-07 |
2024-02-14 |
Century Therapeutics, Inc. |
Kombiniertes polypeptid aus künstlichem zelltod/reportersystem für chimäre antigenrezeptorzellen und verwendungen davon
|
BR112023018844A2
(pt)
|
2021-04-07 |
2023-10-10 |
Century Therapeutics Inc |
Composições e métodos para geração de células t gama-delta de células-tronco pluripotentes induzidas
|
WO2022216624A1
(en)
|
2021-04-07 |
2022-10-13 |
Century Therapeutics, Inc. |
Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
|
JP2024516992A
(ja)
|
2021-05-05 |
2024-04-18 |
フジフィルム セルラー ダイナミクス,インコーポレイテッド |
Ipsc由来ミクログリアのための方法及び組成物
|
CN117881777A
(zh)
|
2021-05-26 |
2024-04-12 |
富士胶片细胞动力公司 |
防止多能干细胞中基因快速沉默的方法
|
AU2022283291A1
(en)
|
2021-05-27 |
2023-11-02 |
Sana Biotechnology, Inc. |
Hypoimmunogenic cells comprising engineered hla-e or hla-g
|
CN113429487B
(zh)
*
|
2021-06-21 |
2022-04-22 |
山东大学 |
一种能在水环境中去除抗生素耐药基因的人工合成蛋白
|
AU2022309875A1
(en)
|
2021-07-14 |
2024-01-25 |
Sana Biotechnology, Inc. |
Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
|
EP4377459A2
(de)
|
2021-07-30 |
2024-06-05 |
Tune Therapeutics, Inc. |
Zusammensetzungen und verfahren zur modulation der expression von frataxin (fxn)
|
WO2023010135A1
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
KR20240053673A
(ko)
|
2021-08-11 |
2024-04-24 |
사나 바이오테크놀로지, 인크. |
저면역원성 세포 내 유전자 발현을 변경하기 위한 유도성 시스템
|
CA3227108A1
(en)
|
2021-08-11 |
2023-02-16 |
Xiaomeng HU |
Genetically modified primary cells for allogeneic cell therapy
|
AU2022325955A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
AU2022326565A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
WO2023019227A1
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
WO2023039567A2
(en)
|
2021-09-10 |
2023-03-16 |
FUJIFILM Cellular Dynamics, Inc. |
Compositions of induced pluripotent stem cell-derived cells and methods of use thereof
|
US20230128917A1
(en)
|
2021-09-14 |
2023-04-27 |
Crispr Therapeutics Ag |
Genetically engineered immune cells having a disrupted cd83 gene
|
WO2023070043A1
(en)
|
2021-10-20 |
2023-04-27 |
Yale University |
Compositions and methods for targeted editing and evolution of repetitive genetic elements
|
AU2022371442A1
(en)
|
2021-10-21 |
2024-04-18 |
Vertex Pharmaceuticals Incorporated |
Hypoimmune cells
|
WO2023069790A1
(en)
|
2021-10-22 |
2023-04-27 |
Sana Biotechnology, Inc. |
Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
|
WO2023076880A1
(en)
|
2021-10-25 |
2023-05-04 |
Board Of Regents, The University Of Texas System |
Foxo1-targeted therapy for the treatment of cancer
|
US20240034992A1
(en)
|
2021-10-29 |
2024-02-01 |
FUJIFILM Cellular Dynamics, Inc. |
Dopaminergic neurons comprising mutations and methods of use thereof
|
WO2023081756A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
WO2023105244A1
(en)
|
2021-12-10 |
2023-06-15 |
Pig Improvement Company Uk Limited |
Editing tmprss2/4 for disease resistance in livestock
|
WO2023111913A1
(en)
|
2021-12-15 |
2023-06-22 |
Crispr Therapeutics Ag |
Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption
|
US20230346836A1
(en)
|
2021-12-22 |
2023-11-02 |
Crispr Therapeutics Ag |
Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof
|
CA3241193A1
(en)
|
2021-12-22 |
2023-06-29 |
Friedrich A. FAUSER |
Novel zinc finger fusion proteins for nucleobase editing
|
CA3241438A1
(en)
|
2021-12-23 |
2023-06-29 |
Sana Biotechnology, Inc. |
Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
|
WO2023129937A1
(en)
|
2021-12-29 |
2023-07-06 |
Century Therapeutics, Inc. |
Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
|
WO2023131616A1
(en)
|
2022-01-05 |
2023-07-13 |
Vib Vzw |
Means and methods to increase abiotic stress tolerance in plants
|
WO2023131637A1
(en)
|
2022-01-06 |
2023-07-13 |
Vib Vzw |
Improved silage grasses
|
WO2023137471A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
WO2023137472A2
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2023144199A1
(en)
|
2022-01-26 |
2023-08-03 |
Vib Vzw |
Plants having reduced levels of bitter taste metabolites
|
WO2023154578A1
(en)
|
2022-02-14 |
2023-08-17 |
Sana Biotechnology, Inc. |
Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
TW202340457A
(zh)
|
2022-02-28 |
2023-10-16 |
美商凱特製藥公司 |
同種異體治療細胞
|
WO2023166425A1
(en)
|
2022-03-01 |
2023-09-07 |
Crispr Therapeutics Ag |
Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
WO2023180904A1
(en)
|
2022-03-21 |
2023-09-28 |
Crispr Therapeutics Ag |
Methods and compositions for treating lipoprotein-related diseases
|
US20230303713A1
(en)
|
2022-03-23 |
2023-09-28 |
Crispr Therapeutics Ag |
Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof
|
WO2023180967A1
(en)
|
2022-03-23 |
2023-09-28 |
Crispr Therapeutics Ag |
Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruption
|
US20230302423A1
(en)
|
2022-03-28 |
2023-09-28 |
Massachusetts Institute Of Technology |
Rna scaffolded wireframe origami and methods thereof
|
WO2023230613A1
(en)
|
2022-05-27 |
2023-11-30 |
The Broad Institute, Inc. |
Improved mitochondrial base editors and methods for editing mitochondrial dna
|
WO2023240169A1
(en)
|
2022-06-08 |
2023-12-14 |
Century Therapeutics, Inc. |
Immunoeffector cells derived from induced pluripotent stem cells genetically engineered with membrane bound il12 and uses thereof
|
WO2023240212A2
(en)
|
2022-06-08 |
2023-12-14 |
Century Therapeutics, Inc. |
Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
|
WO2023240147A1
(en)
|
2022-06-08 |
2023-12-14 |
Century Therapeutics, Inc. |
Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof
|
WO2023242827A2
(en)
|
2022-06-17 |
2023-12-21 |
Crispr Therapeutics Ag |
LIPID NANOPARTICLES (LNPs)-BASED OCULAR DELIVERY
|
WO2023248147A1
(en)
|
2022-06-21 |
2023-12-28 |
Crispr Therapeutics Ag |
Methods and compositions for in vivo editing of stem cells
|
WO2023248145A1
(en)
|
2022-06-21 |
2023-12-28 |
Crispr Therapeutics Ag |
Compositions and methods for treating human immunodeficiency virus
|
WO2023250511A2
(en)
|
2022-06-24 |
2023-12-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
|
WO2024003786A1
(en)
|
2022-06-29 |
2024-01-04 |
Crispr Therapeutics Ag |
Chimeric antigen receptor targeting gpc-3 and immune cells expressing such for therapeutic uses
|
WO2024006911A1
(en)
|
2022-06-29 |
2024-01-04 |
FUJIFILM Holdings America Corporation |
Ipsc-derived astrocytes and methods of use thereof
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
WO2024013514A2
(en)
|
2022-07-15 |
2024-01-18 |
Pig Improvement Company Uk Limited |
Gene edited livestock animals having coronavirus resistance
|
WO2024020597A1
(en)
|
2022-07-22 |
2024-01-25 |
The Johns Hopkins University |
Dendrimer-enabled targeted intracellular crispr/cas system delivery and gene editing
|
WO2024023801A2
(en)
|
2022-07-29 |
2024-02-01 |
Crispr Therapeutics Ag |
Genetically engineered immune cells having disrupted transporter associated with antigen processing-1 (tap-1) gene
|
WO2024023802A2
(en)
|
2022-07-29 |
2024-02-01 |
Crispr Therapeutics Ag |
Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene
|
WO2024023804A2
(en)
|
2022-07-29 |
2024-02-01 |
Crispr Therapeutics Ag |
Genetically engineered immune cells having disrupted transporter associated with antigen processing binding protein (tapbp) gene
|
WO2024040254A2
(en)
|
2022-08-19 |
2024-02-22 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
WO2024062388A2
(en)
|
2022-09-20 |
2024-03-28 |
Crispr Therapeutics Ag |
Genetically engineered immune cells expressing chimeric antigen receptor targeting cd20
|
WO2024081736A2
(en)
|
2022-10-11 |
2024-04-18 |
Yale University |
Compositions and methods of using cell-penetrating antibodies
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
WO2024102838A1
(en)
|
2022-11-09 |
2024-05-16 |
Century Therapeutics, Inc. |
Engineered interleukin-7 receptors and uses thereof
|
WO2024103017A2
(en)
|
2022-11-10 |
2024-05-16 |
Century Therapeutics, Inc. |
Genetically engineered cells having anti-nectin4 chimeric antigen receptors, and uses thereof
|
WO2024119101A1
(en)
|
2022-12-01 |
2024-06-06 |
Yale University |
Stimuli-responsive traceless engineering platform for intracellular payload delivery
|